Literature DB >> 18060772

Identification and synthesis of a unique thiocarbazate cathepsin L inhibitor.

Michael C Myers1, Parag P Shah, Scott L Diamond, Donna M Huryn, Amos B Smith.   

Abstract

Library samples containing 2,5-disubstituted oxadiazoles were identified as potent hits in a high throughput screen (HTS) of the NIH Molecular Libraries Small Molecule Repository (MLSMR) directed at discovering inhibitors of cathepsin L. However, when synthesized in pure form, the putative actives were found to be devoid of biological activity. Analyses by LC-MS of original library samples indicated the presence of a number of impurities, in addition to the oxadiazoles. Synthesis and bioassay of the probable impurities led to the identification of a thiocarbazate that likely originated via ring opening of the oxadiazole. Previously unknown, thiocarbazates (-)-11 and (-)-12 were independently synthesized as single enantiomers and found to inhibit cathepsin L in the low nanomolar range.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18060772      PMCID: PMC2423727          DOI: 10.1016/j.bmcl.2007.10.107

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  20 in total

Review 1.  The lysosomal cysteine proteases.

Authors:  M E McGrath
Journal:  Annu Rev Biophys Biomol Struct       Date:  1999

Review 2.  Irreversible inhibitors of serine, cysteine, and threonine proteases.

Authors:  James C Powers; Juliana L Asgian; Ozlem Dogan Ekici; Karen Ellis James
Journal:  Chem Rev       Date:  2002-12       Impact factor: 60.622

3.  CA-074, but not its methyl ester CA-074Me, is a selective inhibitor of cathepsin B within living cells.

Authors:  Metwally Montaser; Gilles Lalmanach; Lukas Mach
Journal:  Biol Chem       Date:  2002 Jul-Aug       Impact factor: 3.915

Review 4.  Recent advances in the synthesis, design and selection of cysteine protease inhibitors.

Authors:  Alejandro Alvarez Hernandez; William R Roush
Journal:  Curr Opin Chem Biol       Date:  2002-08       Impact factor: 8.822

5.  Design of potent and selective human cathepsin K inhibitors that span the active site.

Authors:  S K Thompson; S M Halbert; M J Bossard; T A Tomaszek; M A Levy; B Zhao; W W Smith; S S Abdel-Meguid; C A Janson; K J D'Alessio; M S McQueney; B Y Amegadzie; C R Hanning; R L DesJarlais; J Briand; S K Sarkar; M J Huddleston; C F Ijames; S A Carr; K T Garnes; A Shu; J R Heys; J Bradbeer; D Zembryki; L Lee-Rykaczewski; I E James; M W Lark; F H Drake; M Gowen; J G Gleason; D F Veber
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

6.  The crystal structure of human cathepsin L complexed with E-64.

Authors:  A Fujishima; Y Imai; T Nomura; Y Fujisawa; Y Yamamoto; T Sugawara
Journal:  FEBS Lett       Date:  1997-04-21       Impact factor: 4.124

7.  Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry.

Authors:  Graham Simmons; Dhaval N Gosalia; Andrew J Rennekamp; Jacqueline D Reeves; Scott L Diamond; Paul Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-04       Impact factor: 11.205

8.  Identification and characterization of 3-substituted pyrazolyl esters as alternate substrates for cathepsin B: the confounding effects of DTT and cysteine in biological assays.

Authors:  Michael C Myers; Andrew D Napper; Nuzhat Motlekar; Parag P Shah; Chun-Hao Chiu; Mary Pat Beavers; Scott L Diamond; Donna M Huryn; Amos B Smith
Journal:  Bioorg Med Chem Lett       Date:  2007-07-05       Impact factor: 2.823

9.  From good substrates to good inhibitors: design of inhibitors for serine and thiol proteases.

Authors:  R Baggio; Y Q Shi; Y Q Wu
Journal:  Biochemistry       Date:  1996-03-19       Impact factor: 3.162

10.  Cysteine protease inhibition by azapeptide esters.

Authors:  J Magrath; R H Abeles
Journal:  J Med Chem       Date:  1992-11-13       Impact factor: 7.446

View more
  12 in total

1.  Enzyme microarrays assembled by acoustic dispensing technology.

Authors:  E Y Wong; S L Diamond
Journal:  Anal Biochem       Date:  2008-06-20       Impact factor: 3.365

2.  Kinetic characterization and molecular docking of a novel, potent, and selective slow-binding inhibitor of human cathepsin L.

Authors:  Parag P Shah; Michael C Myers; Mary Pat Beavers; Jeremy E Purvis; Huiyan Jing; Heather J Grieser; Elizabeth R Sharlow; Andrew D Napper; Donna M Huryn; Barry S Cooperman; Amos B Smith; Scott L Diamond
Journal:  Mol Pharmacol       Date:  2008-04-10       Impact factor: 4.436

3.  Design, synthesis, and evaluation of inhibitors of cathepsin L: Exploiting a unique thiocarbazate chemotype.

Authors:  Michael C Myers; Parag P Shah; Mary Pat Beavers; Andrew D Napper; Scott L Diamond; Amos B Smith; Donna M Huryn
Journal:  Bioorg Med Chem Lett       Date:  2008-05-01       Impact factor: 2.823

4.  Molecular docking of cathepsin L inhibitors in the binding site of papain.

Authors:  Mary Pat Beavers; Michael C Myers; Parag P Shah; Jeremy E Purvis; Scott L Diamond; Barry S Cooperman; Donna M Huryn; Amos B Smith
Journal:  J Chem Inf Model       Date:  2008-07-04       Impact factor: 4.956

5.  Design, synthesis and biological evaluation of a library of thiocarbazates and their activity as cysteine protease inhibitors.

Authors:  Zhuqing Liu; Michael C Myers; Parag P Shah; Mary Pat Beavers; Phillip A Benedetti; Scott L Diamond; Amos B Smith; Donna M Huryn
Journal:  Comb Chem High Throughput Screen       Date:  2010-05       Impact factor: 1.339

6.  A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells.

Authors:  Parag P Shah; Tianhua Wang; Rachel L Kaletsky; Michael C Myers; Jeremy E Purvis; Huiyan Jing; Donna M Huryn; Doron C Greenbaum; Amos B Smith; Paul Bates; Scott L Diamond
Journal:  Mol Pharmacol       Date:  2010-05-13       Impact factor: 4.436

7.  Advancing microarray assembly with acoustic dispensing technology.

Authors:  E Y Wong; S L Diamond
Journal:  Anal Chem       Date:  2009-01-01       Impact factor: 6.986

8.  The HIV Protease Inhibitor Saquinavir Inhibits HMGB1-Driven Inflammation by Targeting the Interaction of Cathepsin V with TLR4/MyD88.

Authors:  John P Pribis; Yousef Al-Abed; Huan Yang; Domokos Gero; Hongbo Xu; Marcelo F Montenegro; Eileen M Bauer; Sodam Kim; Sangeeta S Chavan; Changchun Cai; Tunliang Li; Petra Szoleczky; Csaba Szabo; Kevin J Tracey; Timothy R Billiar
Journal:  Mol Med       Date:  2015-09-02       Impact factor: 6.354

9.  A molten globule-to-ordered structure transition of Drosophila melanogaster crammer is required for its ability to inhibit cathepsin.

Authors:  Tien-Sheng Tseng; Chao-Sheng Cheng; Dian-Jiun Chen; Min-Fang Shih; Yu-Nan Liu; Shang-Te Danny Hsu; Ping-Chiang Lyu
Journal:  Biochem J       Date:  2012-03-15       Impact factor: 3.857

10.  Schizophrenia-Associated hERG channel Kv11.1-3.1 Exhibits a Unique Trafficking Deficit that is Rescued Through Proteasome Inhibition for High Throughput Screening.

Authors:  Nicholas E Calcaterra; Daniel J Hoeppner; Huijun Wei; Andrew E Jaffe; Brady J Maher; James C Barrow
Journal:  Sci Rep       Date:  2016-02-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.